生物制药 - 初级保健医生对口服 GLP-1 类药物的展望-Biopharma-Primary Care Physician Outlook for oral GLP-1s
2025-11-24 01:46
November 24, 2025 12:22 AM GMT Biopharma | North America Primary Care Physician Outlook for oral GLP-1s We conducted a proprietary AlphaWise survey among ~200 US primary care physicians to glean insights into oral and injectable GLP-1 prescribing ahead of the potential launches of LLY's orforglipron and Novo's high-dose oral semaglutide in early 2026. M We expect the FDA to approve two new oral GLP-1 medicines for obesity over the near term - LLY's Orforglipron (1Q26) and Novo's high-dose oral Semaglutide ( ...